3D bioprinted osteosarcoma model for experimental boron neutron capture therapy (BNCT) applications: Preliminary assessment

J Biomed Mater Res B Appl Biomater. 2023 Aug;111(8):1571-1580. doi: 10.1002/jbm.b.35255. Epub 2023 Apr 4.

Abstract

Osteosarcoma is the most frequently primary malignant bone tumor characterized by infiltrative growth responsible for relapses and metastases. Treatment options are limited, and a new therapeutic option is required. Boron neutron capture therapy (BNCT) is an experimental alternative radiotherapy able to kill infiltrative tumor cells spearing surrounding healthy tissues. BNCT studies are performed on 2D in vitro models that are not able to reproduce pathological tumor tissue organization or on in vivo animal models that are expensive, time-consuming and must follow the 3R's principles. A 3D in vitro model is a solution to better recapitulate the complexity of solid tumors meanwhile limiting the animal's use. Objective of this study is to optimize the technical assessment for developing a 3D in vitro osteosarcoma model as a platform for BNCT studies: printing protocol, biomaterial selection, cell density, and crosslinking process. The best parameters that allow a fully colonized 3D bioprinted construct by rat osteosarcoma cell line UMR-106 are 6 × 106 cells/ml of hydrogel and 1% CaCl2 as a crosslinking agent. The proposed model could be an alternative or a parallel approach to 2D in vitro culture and in vivo animal models for BNCT experimental study.

Keywords: 3D bioprinting; 3D cell culture; BNCT; osteosarcoma in vitro model; tumor model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / radiotherapy
  • Boron Compounds
  • Boron Neutron Capture Therapy* / methods
  • Cell Line, Tumor
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / radiotherapy
  • Rats

Substances

  • Boron Compounds